PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Critical Care Medicine and Hospital Infection Prevention and Control, The Second People\'s Hospital of Shenzhen & First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen 518035, China.\', \'Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, China.\', \'Department of Critical Care Medicine, The First Affiliated Hospital, Guizhou University of Chinese Medicine, Guiyang 550001, China.\', \'Department of Nephrology, General Hospital of Central Theater Command of PLA, Wuhan 430070, China.\', \'Department of Critical Care Medicine and Hospital Infection Prevention and Control, The Second People\'s Hospital of Shenzhen & First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen 518035, China. Electronic address: fengyongwen2008@126.com.\', \'Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, China; Key Laboratory of Hot Zone Trauma Care and Tissue Repair of PLA, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, China. Electronic address: Zhifengliu7797@163.com.\', \'Trauma Research Center, Fourth Medical Center and Medical Innovation Research Department of the Chinese PLA General Hospital, Beijing 100048, China. Electronic address: c_ff@sina.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1567-5769(20)31946-910.1016/j.intimp.2020.106873
?:doi
?:hasPublicationType
?:journal
  • International immunopharmacology
is ?:pmid of
?:pmid
?:pmid
  • 32795897
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.051
?:rankingScore_hIndex
  • 94
is ?:relation_isRelatedTo_publication of
?:title
  • Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all